Welcome to our dedicated page for Harpoon Therapeutics news (Ticker: HARP), a resource for investors and traders seeking the latest updates and insights on Harpoon Therapeutics stock.
Harpoon Therapeutics (HARP) is a clinical-stage biotech company pioneering T-cell redirecting treatments for cancer. This page provides investors and researchers with essential updates on clinical developments, research breakthroughs, and strategic partnerships.
Access timely press releases covering trial milestones, regulatory filings, and scientific publications. Our curated news collection enables informed tracking of HARP’s tri-specific platform progress and immuno-oncology pipeline advancements.
Key updates include therapeutic candidate developments, intellectual property announcements, and collaboration news with leading research institutions. All content is verified through primary sources to ensure accuracy.
Bookmark this page for centralized access to HARP’s latest advancements in protein engineering and cancer immunotherapy. Check regularly for objective updates on clinical programs and scientific discoveries.
Harpoon Therapeutics (Nasdaq: HARP) has launched an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to buy an additional 15% of shares sold. The net proceeds will fund clinical development of its therapies for various cancers, including HPN424 for prostate cancer and HPN328 for small cell lung cancer, along with advancing other pipeline candidates and general corporate purposes. SVB Leerink and Piper Sandler are managing the offering, which is registered under an SEC shelf statement.
Harpoon Therapeutics announces the clinical development of HPN328, its fourth TriTAC T cell engager, targeting DLL3 for treating small cell lung cancer (SCLC). The first patient was dosed in a Phase 1/2 trial, showcasing preclinical data indicating favorable tolerability and tumor eradication in animal models. The trial aims to assess safety, tolerability, and efficacy in advanced cancers with DLL3 expression. Harpoon's TriTAC platform demonstrates potential for substantial anti-tumor activity, addressing significant unmet needs in SCLC and other neuroendocrine tumors.
Harpoon Therapeutics announced a clinical update on HPN424, showing a confirmed partial response in patients with metastatic castration-resistant prostate cancer (mCRPC). In the highest fixed dose cohort (160 ng/kg), 1 of 7 patients achieved a partial response, with 3 showing PSA reductions. Ongoing dose escalation trials for HPN536 and HPN217 are progressing, with expectations for data readouts in 2021. The company reports that HPN424 was generally well tolerated, with manageable adverse events. A clinical update webcast is scheduled for December 8, 2020.
Harpoon Therapeutics (NASDAQ: HARP) announced a conference call and webcast scheduled for December 8, 2020, at 8 a.m. ET, to provide updates on its leading TriTAC programs. These include HPN424 for metastatic castration-resistant prostate cancer, HPN536 for ovarian and pancreatic cancers, and HPN217 for relapsed/refractory multiple myeloma. The call can be accessed via phone or through the Harpoon website. The company is focused on developing T cell engagers to leverage the immune system against cancers, with several clinical trials underway.
Harpoon Therapeutics announced that CEO Gerald McMahon will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 1-3, 2020. Investors can tune into the pre-recorded chat starting November 23, 2020, via the company's website. The chat will be available through December 3.
Harpoon is developing T cell engagers targeting various cancers, including metastatic prostate cancer and multiple myeloma. Their proprietary TriTAC platform aims to enhance cancer treatment efficacy.
Harpoon Therapeutics (NASDAQ: HARP) presented promising preclinical data for HPN601, a novel T cell engager designed for solid tumors, at the SITC virtual meeting. This is the first conditionally active T cell engager from Harpoon, targeting the EpCAM antigen. Results showed a 10x improved therapeutic index compared to traditional T cell engagers, demonstrating better tolerability and potency in tumor models. HPN601's ability to activate in multiple tumor types paves the way for further clinical development and IND-enabling studies are now underway.
Harpoon Therapeutics, a clinical-stage immunotherapy company (NASDAQ: HARP), announced that CEO Gerald McMahon will present at two virtual investor conferences. The Stifel Virtual Healthcare Conference is scheduled for November 16, 2020, at 10:40 a.m. ET, and he will participate in institutional investor meetings on November 19, 2020, at the SVB Leerink Oncology 1x1 Day. A live audio webcast of the Stifel presentation will be accessible on the company’s website, with an archived replay available later.
Harpoon Therapeutics (NASDAQ: HARP) announced that preclinical data on HPN601 for solid tumors has been accepted for an oral presentation at the 35th Society for Immunotherapy of Cancer (SITC) annual meeting from November 9-14, 2020. HPN601, targeting the EpCAM tumor antigen, utilizes Harpoon’s ProTriTAC™ platform, which activates T cell engagers at tumor sites, potentially improving safety. The presentation is scheduled for November 12, 2020, by Dr. Jack Lin. A copy will be available on the company’s website following the event.
Harpoon Therapeutics (HARP) reported a net loss of $13.3 million for Q3 2020, down from $15.9 million in Q3 2019, amid rising revenue of $3.9 million, up from $1.4 million year-over-year, primarily from an agreement with AbbVie.
The firm is advancing its TriTAC pipeline and plans to initiate a Phase 1/2 trial for HPN328 targeting small cell lung cancer. It ended Q3 with $162.3 million in cash, reflecting a solid financial position. The company is navigating the COVID-19 pandemic without significant operational delays.
Harpoon Therapeutics (NASDAQ: HARP) has appointed Omer Siddiqui as Vice President of Development Operations and Project Management. Siddiqui brings a wealth of experience from Alector, where he oversaw clinical development planning for multiple antibody programs. His expertise in oncology will enhance Harpoon's growing clinical portfolio, particularly its T cell engagers aimed at treating solid tumors and hematologic malignancies. Current product candidates include HPN424, HPN536, HPN217, and HPN328, each targeting specific cancers and in various phases of clinical trials.
FAQ
What is the market cap of Harpoon Therapeutics (HARP)?
